The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence Monitoring

NCT ID: NCT02647164

Last Updated: 2016-01-06

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 360 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2016-01-31

Brief Summary

The purpose of this study is to assess the value of circulating tumor cells (CTC)for non-small cell lung cancer in the postoperative recurrence monitoring by comparing the CTCs, CT and tumor markers at different time points.The time of CTC and carcinoembryonic antigen(CEA) detection is baseline, 2~7 days, 3 months, 6 months, 12 months, 24 months, 36 months after the surgery. And the time of CT detection is 6 months, 12 months, 24 months, 36 months after the surgery.

Conditions

Non-small-cell Lung Carcinoma

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Age 18-80 years old
• Patients with histologically documented (stage Ⅰ/Ⅱ/ⅢA ) non-small cell lung cancer.
• Patients will undergo surgery.
• Patients with preoperative CTCs ≥8.5 Units / 3 ml
• Informed consent must be obtained from all patients prior to beginning therapy. Patients should have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

• Patients with histologically documented not (stage Ⅰ/Ⅱ/ⅢA ) non-small cell lung cancer.
• After the operation review, patients' result of CTC, CT and tumor markers is incomplete at the same point.
• The blood sample isn't collected in predetermined time.
• The blood samples appear hemolysis.
• The blood sample isn't enough.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GenoSaber

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

CTC2015-01

Identifier Type: -

Identifier Source: org_study_id